NCT04821622
Despite recent advances in the treatment of metastatic prostate cancer, more treatment options are needed.
The TALAPRO-3 study is researching whether talazoparib, the study drug, is safe and effective when given to men with metastatic Castration-Sensitive Prostate Cancer (mCSPC) along with enzalutamide, an approved treatment for this condition.
Who may participate
Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.
What to expect
Clinic or phone contact every 8 to 12 weeks unless imaging is required
Some studies require the study team to stay in contact with the participant for a period of time after the participant completes the main part of the study. This long-term follow up is to collect additional information on the study drug over time.
About metastatic Castration-Sensitive Prostate Cancer (mCSPC)
About metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Prostate cancer occurs when the cells within the prostate gland start to multiply out of control. It is the second most common cancer in American men, after skin cancer.
Initial treatment may involve surgery or radiation to remove the cancer when it is localized to the prostate; it may also involve medication that aims to keep levels of the male sex hormones low. This is because prostate cancer growth is often driven by male sex hormones, including testosterone.
If the cancer continues to spread to other parts of the body, or if it is first diagnosed when it has already spread beyond the prostate, the condition is known as metastatic Castration-Sensitive Prostate Cancer, however it may still be responsive to hormone therapy.

About DNA Damage Response (DDR)
About DNA Damage Response (DDR)
DNA is found in all cells and is arranged into structures called genes. Different genes contain information to produce different proteins. Sometimes DNA can have certain defects or errors. Some proteins are important to help cells find and fix errors in other genes (DNA damage response).
To enroll in this study, you must have a DNA defect in one of 12 genes important for DNA damage response, such as: ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, or RAD51C.
Therefore, you may be asked to provide a blood and tumor sample to determine if your tumor DNA has any of these defects. The tumor sample will be provided either through a biopsy (a procedure to remove a piece of tissue) or from tumor tissue that was previously obtained.
